Source link : https://www.newshealth.biz/health-news/which-tnbc-patients-benefit-from-adjuvant-chemo/
TOPLINE: Patients with early-stage triple-negative breast cancer (TNBC) and high immune infiltration showed improved disease-free survival (DFS) with adjuvant capecitabine. These “immune-hot” patients had a 5-year DFS rate of 96.9% compared with 79.4% in the control group. METHODOLOGY: In some studies, adding extended capecitabine to standard adjuvant chemotherapy has been shown to improve DFS in […]
Author : News Health
Publish date : 2024-10-22 12:00:43
Copyright for syndicated content belongs to the linked Source.
